Demonstrate the value of vaccines: 7 updates examining NITAG and HTA requirements

Health economics and outcomes research (HEOR) and market access teams responsible for vaccines need a deep understanding of evaluation requirements from national immunization technical advisory groups (NITAGs) and health technology assessment (HTA) agencies.

Read these seven updates to gain:

• an understanding of the global requirements of NITAGs and HTA agencies for vaccine evaluation
• insights into which stakeholders are involved in vaccine evaluation, and global NITAG and HTA requirements
• an appreciation of the differences in vaccine modeling requirements among markets
• recommendations for developing global value dossiers that meet the needs of NITAGs and HTA agencies.

The role of NITAGs and HTA agencies in decision-making for vaccines

Discover which key stakeholders are involved in the approval of new vaccines, gain insight into the role of NITAGs in decision-making for vaccines, and consider the varying role of HTA agencies in the vaccine appraisal process. Read more

Vaccine appraisals in France: who are the key stakeholders?

Learn more about six of the key stakeholders that are involved in the approval of new vaccines in France. Read more

How pricing models for vaccines vary between countries

Explore the variation in pricing models for vaccines across five countries: Germany, Italy, Spain, the UK, and the US. Read more

Evaluation of vaccines: guidance on evidence and modeling requirements 

Gain a summary of guidance from NITAGs and HTA agencies in Germany, Italy, Spain, the UK, and the US. Read more 

Using economic models and cost-utility analyses to explore the cost-effectiveness of vaccines 

Review the use of economic models and cost-utility analyses in appraisals of the cost-effectiveness of vaccines. Read more

Economic evaluation of vaccines: why is QALY a recommended measure of benefit?

Learn why a quality-adjusted life-year (QALY) is a recommended measure of benefit in the economic evaluation of vaccines, and discover more about health benefits and  the discounting of costs in vaccine economic models across markets. Read more  

How an assessment of NITAG and HTA agency vaccine evidence requirements can help manufacturers establish the value of their vaccine

Find out how an assessment of NITAG and HTA agency vaccine evidence requirements can help manufacturers establish the value of their vaccine with decision-makers. Read more